Zora Bulatovic, MD
Hospitalist · Wailuku, HINPI 1629001227
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Johnson & Johnson at 30.0% of the total. Reporting peaked in 2019 at $293 and has fallen 92.5% since, to $22 in 2023.
Across 21 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$123
- AbbVie$122
- Novartis$57
- Melinta Therapeutics, LLC$50
- AstraZeneca$36
- Portola Pharmaceuticals, LLC$22
What the payments were for
- Food & beverage$409100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $123 |
| AbbVie(2 entities) | 6 | $122 |
| Novartis | 3 | $57 |
| Melinta Therapeutics, LLC | 2 | $50 |
| AstraZeneca | 2 | $36 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
How this compares
$409 in reported general payments places this provider in the 80th percentile of 138 hospitalist providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $12,516 |
| Metoprolol Succinate | 37 | $421 |
| Atorvastatin Calcium | 30 | $384 |
| ClopidogrelClopidogrel Bisulfate | 20 | $273 |
| Amlodipine Besylate | 32 | $217 |
| Levothyroxine Sodium | 13 | $210 |
| Pantoprazole Sodium | 18 | $207 |
| Famotidine | 14 | $176 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $141 |
| Lisinopril | 13 | $131 |
| Furosemide | 19 | $119 |
| Omeprazole | 13 | $104 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $88 |
| Cephalexin | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Wailuku
- Cedric StrongWailuku$1K
- Giedre KarakalpakisWailuku$582
- Deyaa MounirWailuku$471
- Marcelino Yera-PaezWailuku$394
- Christopher ChungWailuku$383
- Ioannis KarakalpakisWailuku$350
- Melody JayneWailuku$317
- Kimberly KowalskiWailuku$263
- Evan BrownWailuku$232
- Susan StewartWailuku$202
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.